Health Care [ 4/12 ] | Biotechnology [ 29/74 ]
NASDAQ | Common Stock
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases.
The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.
It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials.
The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014.
The company was incorporated in 2012 and is based in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 31, 24 | -2.45 Decreased by -2.62 K% | -4.25 Increased by +42.35% |
| Aug 13, 24 | -19.99 Decreased by -14.18 K% | -3.22 Decreased by -520.81% |
| May 15, 24 | -2.28 Decreased by -7.70 K% | -0.20 Decreased by -1.04 K% |
| Mar 27, 24 | -0.04 Increased by +78.95% | -0.10 Increased by +60.00% |
| Nov 2, 23 | -0.09 Decreased by -152.94% | -0.16 Increased by +43.75% |
| Aug 3, 23 | -0.14 Increased by +26.32% | -0.13 Decreased by -7.69% |
| May 11, 23 | 0.03 Increased by +111.11% | -0.04 Increased by +175.00% |
| Mar 23, 23 | -0.19 Increased by +26.92% | -0.17 Decreased by -11.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by -100.00% | -15.54 M Decreased by -90.10% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 302.00 K Decreased by -96.03% | -89.41 M Decreased by -623.56% | Decreased by -29.61 K% Decreased by -18.14 K% |
| Mar 31, 24 | 8.46 M Decreased by -67.44% | -10.33 M Decreased by -442.71% | Decreased by -122.01% Decreased by -1.15 K% |
| Dec 31, 23 | 17.58 M Increased by +72.06% | -5.61 M Increased by +58.05% | Decreased by -31.91% Increased by +75.62% |
| Sep 30, 23 | 12.72 M Decreased by -68.79% | -8.17 M Decreased by -168.69% | Decreased by -64.26% Decreased by -320.06% |
| Jun 30, 23 | 7.61 M Increased by +22.49% | -12.36 M Increased by +5.85% | Decreased by -162.29% Increased by +23.14% |
| Mar 31, 23 | 25.99 M Increased by +265.59% | 3.01 M Increased by +116.46% | Increased by +11.59% Increased by +104.50% |
| Dec 31, 22 | 10.22 M Increased by +41.44% | -13.38 M Increased by +20.39% | Decreased by -130.90% Increased by +43.71% |